Tumbarello M, Tacconelli E, Leone F, Cauda R, Ortona L
Department of Infectious Diseases, Catholic University, Rome, Italy.
Eur J Gastroenterol Hepatol. 1995 Mar;7(3):259-63.
To evaluate the prevalence of, risk factors for, treatment and outcome of Clostridium difficile-associated diarrhoea (CDAD) in patients with human immunodeficiency virus (HIV) infection.
A prospective case-control study, conducted between January 1992 and April 1994.
Department of Infectious Diseases in a large university hospital with HIV in- and out-patient units.
The study included 124 patients grouped as follows: 31 HIV-infected patients with CDAD (group A); 31 HIV-seronegative patients with CDAD (group B) and 62 HIV-infected patients without CDAD (group C). The patients in group B and C were selected randomly during the study period.
The prevalence of CDAD in HIV-infected patients was 3.1% compared with 1.6% in HIV-seronegative patients (P = 0.02). On univariate analysis, the predisposing factors in group A were antibiotic use in the 4 weeks prior to the onset of CDAD (P = 0.03 versus group C), prolonged hospitalization (over 20 days; P = 0.04), low levels of circulating CD4+ cells (P = 0.03) and use of antacids (P = 0.04). The antibiotics significantly associated with CDAD were trimethoprim-sulfamethoxazole (P = 0.02 versus group C), third generation cephalosporins (P = 0.03) and clindamycin (P = 0.03). On multivariate analysis of the risk factors, the use of antibiotics was the sole independent risk factor for CDAD (P = 0.03). The clinical symptoms of CDAD were more severe in HIV-infected patients than in controls. Three patients in group A (9.7%) had one relapse and one patient (3.2%) experienced chronic diarrhoea. The outcome of CDAD was not influenced by the number of circulating polymorphonuclear cells and CD4+ cells. No difference in the survival curves of AIDS patients with or without CDAD, stratified according to age, sex and CD4+ cell count was observed.
Our data suggest that CDAD is more common in HIV-infected patients, particularly those receiving antibiotic therapy, than in HIV-seronegative patients. Since C. difficile can cause severe and recurrent or chronic infections in HIV-infected patients, CDAD must be always considered in the differential diagnosis of diarrhoea in patients with AIDS and AIDS-related conditions.
评估人类免疫缺陷病毒(HIV)感染患者中艰难梭菌相关性腹泻(CDAD)的患病率、危险因素、治疗及预后情况。
1992年1月至1994年4月进行的一项前瞻性病例对照研究。
一所设有HIV门诊及住院部的大型大学医院的传染病科。
该研究纳入124例患者,分组如下:31例HIV感染合并CDAD的患者(A组);31例HIV血清学阴性合并CDAD的患者(B组);62例HIV感染但无CDAD的患者(C组)。B组和C组患者在研究期间随机选取。
HIV感染患者中CDAD的患病率为3.1%,而HIV血清学阴性患者中为1.6%(P = 0.02)。单因素分析显示,A组的易感因素为CDAD发病前4周内使用抗生素(与C组相比,P = 0.03)、住院时间延长(超过20天;P = 0.04)、循环CD4+细胞水平低(P = 0.03)以及使用抗酸剂(P = 0.04)。与CDAD显著相关的抗生素为甲氧苄啶 - 磺胺甲恶唑(与C组相比,P = 0.02)、第三代头孢菌素(P = 0.03)和克林霉素(P = 0.03)。对危险因素进行多因素分析时,使用抗生素是CDAD唯一的独立危险因素(P = 0.03)。HIV感染患者中CDAD的临床症状比对照组更严重。A组有3例患者(9.7%)复发1次,1例患者(3.2%)出现慢性腹泻。CDAD的预后不受循环多形核细胞和CD4+细胞数量的影响。根据年龄、性别和CD4+细胞计数分层后,有无CDAD的艾滋病患者生存曲线无差异。
我们的数据表明,CDAD在HIV感染患者中比在HIV血清学阴性患者中更常见,尤其是接受抗生素治疗的患者。由于艰难梭菌可在HIV感染患者中引起严重、复发性或慢性感染,因此在艾滋病患者及艾滋病相关疾病患者腹泻的鉴别诊断中必须始终考虑CDAD。